Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy.

Musolino C, Alonci A, Catena S, Rizzotti P, Russo S, Rotondo F, Allegra A.

Acta Oncol. 2013 Jun;52(5):1050-1. doi: 10.3109/0284186X.2012.732706. Epub 2012 Nov 1. No abstract available.

PMID:
23113590
2.

Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.

Boruah PK, Bolesta S, Shetty SM.

Pharmacotherapy. 2011 Sep;31(9):925. doi: 10.1592/phco.31.9.925.

PMID:
21923596
3.

Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.

Allegra A, Alonci A, Penna G, Russo S, Gerace D, Greve B, D'Angelo A, Catena S, Musolino C.

Hematol Oncol. 2012 Mar;30(1):41-5. doi: 10.1002/hon.1000. Epub 2011 Jun 23. Review.

PMID:
21702057
4.

Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.

Wäsch R, Jakob T, Technau K, Finke J, Engelhardt M.

Ann Hematol. 2012 Feb;91(2):287-9. doi: 10.1007/s00277-011-1235-y. Epub 2011 Apr 15. No abstract available.

PMID:
21494796
5.

Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum high-mobility group-B1 DNA-binding protein induced by lenalidomide administered to treat multiple myeloma.

Inoue Y, Saito T, Tsuruoka Y, Sato K, Nishio Y, Suzuki Y, Kato M, Isobe Y, Sakai H, Takahashi M, Miura I.

Thromb Res. 2013 Oct;132(4):493-4. doi: 10.1016/j.thromres.2013.08.020. Epub 2013 Sep 1. No abstract available.

PMID:
24050827
6.

Thalidomide and lenalidomide in multiple myeloma.

Mazumder A, Jagannath S.

Best Pract Res Clin Haematol. 2006;19(4):769-80. Review.

PMID:
16997182
7.

Lenalidomide: Stevens-Johnson syndrome.

[No authors listed]

Prescrire Int. 2010 Jun;19(107):125. No abstract available.

PMID:
20740722
8.

Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.

Lee MJ, Wickner P, Fanning L, Schlossman R, Richardson P, Laubach J, Castells M.

Br J Haematol. 2014 Oct;167(1):127-31. doi: 10.1111/bjh.12925. Epub 2014 May 14. No abstract available.

PMID:
24824093
9.

Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.

Siniscalchi A, Tendas A, Morino L, Dentamaro T, De Bellis A, Perrotti A, de Fabritiis P, Musto P, Caravita T.

Support Care Cancer. 2012 Jul;20(7):1585-7. doi: 10.1007/s00520-012-1481-0. Epub 2012 May 5. No abstract available.

PMID:
22562584
10.

Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.

García-Muñoz R, Robles-de-Castro D, Muñoz-Rodríguez A, Rabasa P.

Leuk Lymphoma. 2013 Dec;54(12):2753-5. doi: 10.3109/10428194.2013.786072. Review. No abstract available.

PMID:
23488662
11.

Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.

Nakamura N, Kanemura N, Shibata Y, Matsumoto T, Mabuchi R, Nakamura H, Kitagawa J, Goto N, Hara T, Tsurumi H, Moriwaki H.

Leuk Lymphoma. 2014 Jul;55(7):1691-3. doi: 10.3109/10428194.2013.853300. Epub 2014 Jan 28. No abstract available.

PMID:
24138307
12.

Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients.

Castaneda CP, Brandenburg NA, Bwire R, Burton GH, Zeldis JB.

J Clin Oncol. 2009 Jan 1;27(1):156-7. doi: 10.1200/JCO.2008.20.3737. Epub 2008 Dec 1. No abstract available.

PMID:
19047275
13.

Case of angioedema and urticaria induced by lenalidomide.

Uchiyama A, Motegi S, Yamada K, Uehara A, Ishikawa O.

J Dermatol. 2014 Feb;41(2):179-81. doi: 10.1111/1346-8138.12379. Epub 2014 Jan 3. No abstract available.

PMID:
24387621
14.

Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma.

Das A, Sil A, Mishra V, Das NK.

Indian J Pharmacol. 2014 Sep-Oct;46(5):557-9. doi: 10.4103/0253-7613.140598.

15.

Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.

Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P.

JAMA. 2006 Dec 6;296(21):2558-60. Review. No abstract available.

PMID:
17148721
16.

Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.

Zago M, Adam P, Goldschmidt H, Fend F, Kanz L, Weisel K.

Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):e7-e11. doi: 10.1016/j.clml.2013.07.101. Epub 2013 Oct 26. No abstract available.

PMID:
24169269
17.

New immunomodulatory drugs in myeloma.

Lacy MQ.

Curr Hematol Malig Rep. 2011 Jun;6(2):120-5. doi: 10.1007/s11899-011-0077-y. Review.

PMID:
21327565
18.

Severe hypocalcemia due to lenalidomide.

Kong S, Collet P, Marotte H, Thomas T.

Joint Bone Spine. 2015 Oct;82(5):380-1. doi: 10.1016/j.jbspin.2015.01.003. Epub 2015 Feb 25. No abstract available.

PMID:
25726251
19.

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.

Brioli A, Melchor L, Titley I, Vijayaraghavan G, Stephens C, Zeisig A, Pawlyn C, Cavo M, Morilla R, Davies FE, Morgan GJ.

Leuk Lymphoma. 2014 Nov;55(11):2665-8. doi: 10.3109/10428194.2014.900765. Epub 2014 Apr 22. No abstract available.

PMID:
24660850
20.

Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.

Shahan JL, Panu LD, Hildebrandt GC.

Int J Hematol. 2012 Dec;96(6):818-9. doi: 10.1007/s12185-012-1226-3. Epub 2012 Nov 28. No abstract available.

PMID:
23188472

Supplemental Content

Support Center